AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small ...

"With its potential for screening, recurrence monitoring, treatment guidance, and prognosis prediction, utDNA is poised to transform bladder cancer management and personalize patient care." — Liang ...

Bladder cancer is mainly urothelial carcinoma, with non-muscle-invasive and muscle-invasive types, and smoking as a key risk factor. Diagnosis involves cystoscopy, biopsy, urine cytology, and imaging ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the positive readout of Keynote-905 study—also known as EV-303—terms like ...

Aligarh, Jan. 30 -- Aligarh : In a major medical achievement, doctors at Jawaharlal Nehru Medical College and Hospital (JNMCH), Aligarh Muslim University (AMU), successfully performed a complex ...